Dr. Rao & Dr. Nasrazadani – The Second-Line Landscape for HR+/HER2- mBC: The Role of Capivasertib

Description

The second-line landscape for HR+/HER2- metastatic breast cancer is shifting rapidly with the detection of truncal mutations. In this episode of CHM Conversations, Dr. Ruta Rao and Dr. Azadeh Nasrazadani discuss how the detection of PIK3CA, AKT, and PTEN mutations is redefining the role of capivasertib. The clinicians differentiate the clinical application of capivasertib from other targeted agents like alpelisib and inavolisib, exploring how mechanistic differences and biomarker profiles influence patient selection. A central focus is placed on mastering the safety profile of these agents, providing practical strategies for managing stomatitis, diarrhea, and hyperglycemia to ensure treatment continuity and optimize patient outcomes. An essential resource for oncology teams navigating the complexities of the PI3K/AKT/PTEN pathway and optimizing supportive care in the second-line metastatic breast cancer landscape. 🎧 Watch more expert-led oncology conversations from CHM Conversations. #BreastCancer #HRPositive #MetastaticBreastCancer #PrecisionOncology #BiomarkerTesting #PIK3CA #ESR1 #Capivasertib #LiquidBiopsy #EndocrineTherapy #CommunityHealthMedia – Thanks for watching! Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o – Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts Learn more about us here - https://communityhealth.media

Dr. Rena Callahan & Dr. Aditya Bardia - Integrating T-DXd in HER2+ Breast Cancer: DB11, DB05 & DB09

HER2-positive breast cancer treatment is evolving rapidly. With FDA approvals from DESTINY-Breast11 and DESTINY-Breast05, when should clinicians incorporate trastuzumab deruxtecan (T-DXd) into practice—and how should it be used across early-stage and into metastatic disease? In this in-depth discussion, Dr. Rena Callahan and Dr. Aditya Bardia explore how these landmark studies are changing treatment decisions today across neoadjuvant, adjuvant, and metastatic settings—including the management of residual disease and the optimization of first-line metastatic care.Key topics discussed: * How DESTINY-Breast11 is changing neoadjuvant treatment strategies * DESTINY-Breast05 and the role of T-DXd for residual disease * Which patients should receive T-DXd versus T-DM1 * Managing ILD risk and monitoring requirements * Treatment decisions for patients who do not achieve pCR * Rechallenging T-DXd after recurrence * First-line metastatic HER2-positive breast cancer after DESTINY-Breast09 * Deep responses, complete responses, and long-term outcomes * T-DXd versus THP in clinical practice * PATINA, HER2CLIMB-05, and evolving maintenance strategies * CNS metastases and the role of HER2-targeted ADCs * Treatment holidays, ctDNA monitoring, and personalized care As T-DXd moves into earlier lines of therapy, oncologists are facing new questions around sequencing, toxicity management, and optimizing long-term outcomes. This conversation provides practical insights for both academic and community clinicians navigating this rapidly changing landscape. Subscribe for more expert oncology discussions, breast cancer updates, and clinical trial insights from Community Health Media. –Thanks for watching!Our podcasts are also available on: * Spotify - ⁠https://spotf.fi/chm-podcast⁠ [https://www.youtube.com/redirect?event=video_description&redir_token=QUM4Zm9rU3dXcUwwZnMxczcybEo2alU3NHFPVXxBR3JiS2FrOEU4N3l3dzJrVXlNQ0loaDA2dTZDWmpnY2pmNksxZTRzLW96UVNwQ1NQaDdTSmxadlRvRG5qdjdjOFN1MlU4V0tZQTJ6RTA1aFhoUXFudVgyVktjTTEwZzI1WXd6&q=https%3A%2F%2Fspotf.fi%2Fchm-podcast&v=h9EkMSpdP-U] * Amazon Music - ⁠https://amazn.so/chm-podcast⁠ [https://www.youtube.com/redirect?event=video_description&redir_token=QUM4Zm9rUTNvM2l4ZGJVandrTHQzUXVmTGpveHxBR3JiS2FsMVRnNU82T09PRS1RZTRRTGpQMHl3U0J0V3hWWE81VjRkZ1ppQ0JTczRsZGxLdnpZb3FaOVFoZ0s2RnpQQ2QxeUktRzhGSUZNUXJka2FCTnJzcVNsRldQLXUwaTQ1&q=https%3A%2F%2Famazn.so%2Fchm-podcast&v=h9EkMSpdP-U] * Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠ [https://www.youtube.com/redirect?event=video_description&redir_token=QUM4Zm9rVGxHdzZROWlYS2xFZS1RNHNLUGlNN3xBR3JiS2FuS1JFUVFZVEwxTVZ2anV5WURwSVlrUjFaMGhVM0FYWmpDRFRMeFBfQmVfUDdjQk9aWEREMVd4ekVfcHAwUVY5T3pHM0xhVUFyLTEwQjhWQmxmVUZoZUJKb0dBVVc5&q=https%3A%2F%2Fpodcasts.apple.com%2Fus%2Fpodcast%2Fcommunity-health-media%2Fid1837428248&v=h9EkMSpdP-U] * Castbox - ⁠https://castbox.fm/vh/6735434⁠ [https://www.youtube.com/redirect?event=video_description&redir_token=QUM4Zm9rU3JWcklRVjNRUFJoQmozdTNoVmdvX3xBR3JiS2FubGN4UG8yQ05CZmRIZU9TektBc2k4OVRDbDRBX0lDUUVSRUZaV0hMUXM3SUR4UnlEYS1McDJPbjJNWjg5bmRmeDhsd1A5ZE1OQ1dfN3NkaGw0dHE4ekFwSXNIUVFO&q=https%3A%2F%2Fcastbox.fm%2Fvh%2F6735434&v=h9EkMSpdP-U] * Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠ [https://www.youtube.com/redirect?event=video_description&redir_token=QUM4Zm9rU2tmZXEyTkl2RnpQODI5Q1EwSF91NnxBR3JiS2FsZHhvNFVNdzNwQk8zV05pdWRFWHVyOWIzYlVGYXotd0RsRVlmR1REelZKaGxyS05yXzJROHNjMjNlVDRaM1MyMEFydTQ3SWJHZGRNQVhPU1k4NDZ4MjBpdzNseVpp&q=https%3A%2F%2Fgoodpods.com%2Fprofile%2Fchm-111066&v=h9EkMSpdP-U] * iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠ [https://www.youtube.com/redirect?event=video_description&redir_token=QUM4Zm9rUWlkaUdlV0pjaUNqRjVraDB0eEszNnxBR3JiS2FrTjF3SHVjbmlyZlU0eGhPanpnWEwwQkVRblJtREpjTjBwdHBWcHlsZldmZVVuLVN5ZnA2QVVRZC1EdElSOFdvcVJNdF9ZSG5aUmJJQldFS2hkbDRuVzZDTlI1eUVC&q=https%3A%2F%2Fiheart.com%2Fpodcast%2F291542082&v=h9EkMSpdP-U] * Pocket Casts - ⁠https://pca.st/3ncdh11o⁠ [https://www.youtube.com/redirect?event=video_description&redir_token=QUM4Zm9rUThNY1hvQmpoRHRxenZza1JxaFpXTnxBR3JiS2Fub0l1dHFnVnJBYzhuOW5wTzhHTGhVbFhhdC1YNFpCdUJmUzZ0Q1lIYmhjY1BxeC05WTQ4WmJ3WWpaUVNYSDFSUXdpRWdDZno0aWZjLWlkb3FKay1La09mdGhXZzFz&q=https%3A%2F%2Fpca.st%2F3ncdh11o&v=h9EkMSpdP-U] –Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: * Peer to peer interviews, panels & round-tables * Curated live events & conferences * Professional in-depth content & research updates * Interactive learning modules & webinars * Live & on-demand webcasts & podcasts Learn more about us here - ⁠https://communityhealth.media⁠ [https://www.youtube.com/redirect?event=video_description&redir_token=QUM4Zm9rU3NyMHdZOXFZeU1FV1hlSzJXU1FKVXxBR3JiS2FtX19LbkNnTEVSR3YwN2FLUnNFUC1wUUpFZXhxMF8wNFNqWlBtRnRlS1d0emJKM3ZmTU94MUdOSG5aZHRJUmpsUG05NkpOVlpBNlNpNlJGWHVuVmVlc09hVFFvVWRD&q=https%3A%2F%2Fcommunityhealth.media%2F&v=h9EkMSpdP-U]

26. juni 202632 min

Dr. Rao & Dr. Nasrazadani – The Second-Line Landscape for HR+/HER2- mBC: The Role of Capivasertib

Description

Comments

1 month for 9 kr.

All episodes